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Abstract: Introduction and Aims: The trajectories of cannabis use disorder (CUD) require more comprehensive 
delineation to expedite recognition of incubating dependence among high-risk users. This study examined baseline 
cannabis use and CUD over 12 months using DSM-IV/ICD10 diagnoses to distinguish transition groups. 
Design and Methods: In a prospective naturalistic design, 194 heterogeneous cannabis users (128 adolescents, 66 adults) 
aged 13-61 years were voluntarily recruited and assessed at baseline, and then re-assessed 12-months later. 
Results: Most participants met criteria for a baseline CUD (70% dependence, 20% abuse), 12 adolescents were 'diagnostic 
orphans', and 5 symptom-free. At follow-up, 25% adolescents reported using less, 6% the same level, and 69% using more 
cannabis. Significantly increased symptoms and dependence severity were reported, with no adolescent/adult differences 
evident. Three diagnostic transition groups were identified. While 84% adolescents (n=108) remained stable, 5% (n=7) 
had improved, 10% (n=13) had deteriorated. ‘Deteriorators’ scored significantly higher than ‘improvers’ on cannabis use, 
symptoms, and dependence severity measures. A subjective loss of control over cannabis use was among the earliest 
DSM-IV features among younger users on a trajectory towards dependence. Most participants (79%) anticipated difficulty 
trying to reduce/quit their use 
Discussion and Conclusions: Younger adolescents can rapidly develop cannabis dependence, reporting similar and 
equally severe symptoms as longer-term adult users. 
Impaired control over use occurs early in trajectories towards dependence. The seeming intractability of problematic 
cannabis use calls for concerted cannabis screening and early intervention (SEI) efforts at an earlier age to avert or reduce 
harmful consequences of cannabis use in the community. 
Keywords: Cannabis, cannabis dependence, cannabis use trajectories, marijuana, public health SEI, screening. 
INTRODUCTION 
 Cannabis is by far the most widely used illegal drug 
worldwide, estimated at approximately 4.5% of the global 
population aged from 15 years [1] with much higher rates 
among adolescents [2-4]. A marked increase in cannabis 
treatment-seeking, particularly among younger users, calls 
for a concerted public health response to cannabis-related 
harms [2-4]. 
 Adolescence is a biological and developmental period of 
addiction vulnerability [5]. Cannabis dependence develops 
twice as rapidly in adolescents than adults at any 
consumption level [6-9]; approximately 14-16% adolescent-
onset and 8% adult-onset users become dependent [3]. While 
early cannabis initiation and entrenched use confer the 
highest risk of dependence and other adverse outcomes  
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 [7-11], even occasional (weekly) use continued into young 
adulthood predicts later drug and other problems [12-14]. 
Recognizing early manifestations of cannabis use disorder 
(CUD) is crucial for identifying those for whom timely 
intervention might avert further harm. As yet, relatively little 
is known about the natural history of cannabis dependence 
[15]. 
 Adolescents from the 1970’s typically initiated cannabis 
use around 15-18 years, used ‘experimentally’/intermittently, 
and discontinued by the mid-to-late twenties [16]. However, 
incidence, escalation, and persisting cannabis use and CUD 
was a nascent trend in more recent prospective studies of 
cohorts aged in their mid-late 20s [10, 14, 17-22] and 30s 
[13, 16]. Cannabis use appears less transient than previously 
thought. Other age-related trends in recent decades are pre-
adolescent cannabis initiation, and prolongation of initiation 
risk beyond adolescence [20]. 
 Researchers have begun modeling cannabis use 
trajectories spanning adolescence through early-mid 
adulthood [10, 21-23]. For example, prototypical subgroups 
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include: high chronic, decreasers, increasers, experimental 
users, abstainers, ‘fling’, rare. Conjoint/comorbid cannabis, 
alcohol, and tobacco use trajectories are also appearing [14, 
24-26]. 
 Another natural history approach involves temporal 
patterning of symptoms among users on a trajectory to 
dependence; a ‘subjective loss of control’ was among the 
earliest, most prevalent DSM-III-R features [27-29]. 
Likewise, Australian users aged 20-21 years most frequently 
endorsed DSM-IV ‘persistent desire to cut down/control use’ 
(10%; 91% dependent users) and ‘used more/longer than 
intended’ (8%; 84% dependent users) [30]. US adolescents 
aged 12-18 years [31] reported ‘continued use despite a 
physical/psychological problem’ (45%; 60% dependent 
users) ‘tolerance’ (35%; 51% dependent users), and ‘used 
more/longer than intended’ (21%; 35% dependent users). By 
contrast, frequent and infrequent German adolescent users 
aged 14+ years reported similar symptoms, with withdrawal 
(17%), tolerance (15%), and loss of control (14%), most 
prevalent [32]. 
 The variability in the symptoms pattern in these studies 
appears partly related to consumption level and design 
effects, such as age composition, period, country, 
recruitment origins, diagnostic assessments versus 
retrospective recall, and ‘risk’ level among samples. As yet, 
no prospective studies with mixed adolescent-adult 
community samples have been reported. 
 New Zealand is a world leader in per capita cannabis use 
[33]. Almost half (46.4%) of New Zealanders report lifetime 
use, and one in seven past year use [34]. Significantly higher 
use (one in four) is reported among New Zealand’s 
indigenous Maori population [35]. Given both rising 
consumption and ever-younger initiation worldwide [33, 36] 
cannabis use and disorder trajectories require more 
comprehensive delineation to expedite recognition of 
incubating dependence in order to intervene effectively 
among younger high-risk users. To supplement the sparse 
literature on the natural history of cannabis use and 
dependence development, this paper presents data collected 
in a baseline and 12-month follow-up interview with a mixed 
adolescent-adult sample of at-risk cannabis users recruited in 
New Zealand as part of research aimed at developing a brief 
screener for cannabis problems and reported elsewhere [37]. 
AIMS 
 With adolescent-adult comparisons at both temporal 
points, this study prospectively examined (1) cannabis use 
and CUD in a heterogeneous adolescent-adult community 
sample; (2) the natural history of cannabis use and diagnostic 
transitions 12 months later, and (3) the differential 




 Participants were 138 adolescents (aged 13-18 years) and 
73 adults (19-61 years) from diverse community settings: 
drug treatment (17%; n=6 adolescents, 29 adults); Police 
Youth Aid and alternative education programmes for at-risk 
adolescents (23%, n=48 adolescents); adult justice (3%, n=7 
adults); Maori community health services (2%, n=5 adults); 
non-treatment general community (16%, n=14 adolescents, 
19 adults); tertiary students and jobseekers (15%, n=23 
adolescents, 8 adults); secondary school students (24%, n=52 
adolescents). 
 Liberal inclusion criteria required participants had used 
cannabis at least once in the past 12 months, were at least 13 
years of age, English-literate to year eight level to over-
sample younger users, with heterogeneity within both age 
groups. 
 Twelve months later, 95% (n=200) were located and 92% 
(n=194; 128 adolescents, 66 adults) re-interviewed. 
Participants lost to follow-up (10 adolescents, 7 adults) had 
either left the region/ country (n=8), failed to return multiple 
phone calls/declined interview (n=6), or were in 
prison/juvenile detention (n=3). Although predominantly 
male (70%), the roughly proportional drop-out across 
adolescent/adult groups indicated no selective attrition due to 
age or recruitment setting. 
Assessment 
 A face-to-face interviewer-administered schedule and 
self-completed instruments assessed: demographics, 
cannabis use, other drug use, CUD, dependence severity, 
general and psychological health, cannabis-related problems, 
quit attempts, and treatment-seeking. Only key measures 
relevant to the present study aims are reported here. 
 Current (90-day) cannabis consumption was assessed 
using the Timeline Followback interview (TLFB) [38, 39]. 
The Syva EMIT urinalysis procedure verified clinical 
participants’ (n=40) self-reported consumption [40]. Other 
drug use was recorded using the Drug History Questionnaire 
(DHQ) [41]. Twelve-month CUD diagnoses from the 
Diagnostic and Statistical Manual of Mental Disorders, 
fourth revision (DSM-IV) [42], and the International 
Classification of Diseases tenth revision (ICD10) [43] were 
obtained using the Drug Use module of the Composite 
International Diagnostic Interview (CIDI)-Auto, version 2.1 
[44]. The Severity of Dependence Scale (SDS) [45] provided 
another measure of 6-month CUD. 
 At follow-up, modified measures ascertained 12-month 
change in cannabis use and disorder. The CIDI-Auto, the 
TLFB interview, and the SDS were re-administered as at 
baseline. 
Procedure 
 This study received institutional ethical approval. The 
absence of a sampling frame of cannabis users in the 
community ruled out assembly of a random representative 
sample from this “hidden population” [46]. Voluntary, non-
reimbursed participants were recruited utilizing procedures 
apposite for population subgroups and recruitment settings. 
The recruitment strategy featured initial invitation to 
participate by: clinicians to eligible drug treatment clients; 
Youth Aid and Probation Officers to at-risk adolescents and 
adult offenders, respectively; campus counsellors or nurse to 
tertiary, work training, and secondary school students, and 
on-campus A4 invitation poster displays. To preserve 
recruitment integrity among specific subgroups, the 
researcher provided brief training and checklist-type 
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guidelines for recruitment personnel. Additionally, a chain-
referral ‘snowball sampling’ [46] technique, in which the 
researcher seeks contacts or referrals from participants to 
other cannabis users in their social networks, was employed 
among general population participants. This strategy has 
been used successfully to access similar “hidden 
populations” [46]. Clinician certification of competence, 
recruitment officer and parent/guardian signatures, or 
Principal/Board of Trustees’ permission, was obtained for 
participants under 16 years. All participants signed informed 
consent. 
 All assessment interviews were conducted by the 
principal investigator (JB) at participant-elected times and 
venues. Baseline interviews were conducted between 
December 2003 and August 2005 at drug treatment clinics, 
various community interview rooms, student health services, 
participants’ own homes, a community youth support facility 
and, occasionally, in private areas in cafes and taverns. 
Assured that their non-identifiable data would remain 
accessible to only the interviewer, respondents were thanked, 
reminded to expect follow-up contact in 12 months, and 
verified their tracking/locator details. Follow-up interviews 
were conducted approximately 12 months later (mean 366 
days; SD=10.09, range: 318-407). Most (77%) were face-to-
face, 20% by telephone, and 3% by post/email. Treatment 
information was provided if requested or indicated at both 
assessments. 
Data Analyses 
 Data were analysed using SPSS for Windows Version 
12.0 [47]. Descriptive statistics with adolescent/adult 
comparisons on cannabis use, symptoms, diagnoses, 
dependence severity, and other drug use at both temporal 
points are presented. We calculated participants’ diagnostic 
change at 12-month follow-up and distinguished 3 common 
transition groups (stable/same diagnosis, improved/less 
severe diagnosis, deteriorated/more severe diagnosis). A 
series of t-tests were then conducted to examine the 
differential association between transition group membership 
(improved vs deteriorated) and the key variables in this 
study. 
RESULTS 
 There were no significant differences between the 
follow-up (n=194) and lost to follow-up (n=17) samples in 
terms of age, education, severity of dependence, and 
psychological health (anxiety, depression). The lost to 
follow-up sample had reported significantly more cannabis 
use in the past 90 and past 30 days, and significantly more 
symptoms (all p< .01). All descriptive and inferential 
statistics reported are based on the follow-up N of 194. 
Sociodemographics 
 Participants were 70% Caucasian, 25% Maori (New 
Zealand’s indigenous population), and 5% Maori/Caucasian. 
The mean age was 20.5 years (range: 13-61); 56% (N=118) 
were male. Participants’ generally low educational and 
socioeconomic status reflected in unemployment rates which 
persisted at follow-up (12-13% were in full-time 
employment). Almost one-third of adolescents (30%) 
reported their parent/s used cannabis regularly. More than 
half the sample (53 versus 45% at baseline) reported being in 
a relationship, with most (66% of adolescents, 43% of 
adults) having partners who also used cannabis regularly. 
Cannabis Use 
 Adolescents were significantly younger (mean 12.10 
years, SD=1.8 ) than adults (mean 14.57 years, SD=4.4 ) 
when they first tried cannabis, t (192) = -5.48, p<. 001, and 
began using regularly, t (179) = -7.56, p <.001 (Table 1). 
 At baseline adults reported using significantly more often 
than adolescents over the past 90, t (192) = -3.94, p <. 001, 
and 30 days, t (192) = -4.20, p< .001. At follow-up, however, 
while adults recorded generally-persistent consumption, 
adolescents reported significantly increased use in the past 
90, t (127) = -4.45, p=.001 and 30 days, t (127) = -3.00, 
p<.01. More specifically, while 25% (n=32) adolescents 
were now using less often, 6% (n=8) were using at the same 
level, the majority (69%, n=88) were using more often than 
at baseline. Further, more than half of all adolescents (57%) 
reported using the more potent cannabis preparations. 
 Spearman correlations revealed a significant association 
between laboratory urinalysis data and clinical participants’ 
(n=40) self-reports of consumption over the past 30 days (ϒs 
= .43, p<.01). 
Other Drug Use 
 At baseline, 91% participants reported currently using 
alcohol and 93% tobacco, with no significant 
adult/adolescent differences. Recent/regular use of other 
drugs was not common except for BZP/benzylpiperazine 
(party pills), with 40% reporting past month, and 17% 
weekly, use. At follow-up, 94% reported alcohol use, with 
reduced tobacco use (84 from 93%) across both age groups. 
Two-thirds of adolescents were now drinking significantly 
more often than at baseline, t (123) =-2.36, p<.05. Three-
quarters (83% adolescents, 61% adults) reported 
significantly increased weekly BZP use (52%), t (79) = -
5.56, p<.001. 
Cannabis Use Disorder 
 At baseline, 90% obtained a CUD diagnosis (70% DSM-
IV dependence, 20% abuse, 66% both diagnoses) (Table 2). 
Only 17 participants (8%) had no diagnosis. Of these, 12 
adolescents were ‘diagnostic orphans’ (i.e., met 1-2 
dependence criteria only) [48] and 5 were asymptomatic. 
Adolescents endorsed a mean of 6.1 (SD=3.4, range: 0-13) 
and adults 6.4 (SD=2.8, range: 0-13) from 13 combined 
DSM-IV/ICD-10 symptoms. Most frequently endorsed were: 
‘use in hazardous situations’ (77%), ‘using more/longer than 
intended’ (72%), ‘time spent obtaining, using, or recovering’ 
(64%), and ‘persistent desire to cut down/ control use’ 
(63%). Other than adolescents more likely to report 
cannabis-related work/school or interpersonal problems 
(p<.01), and adults more likely to report withdrawal (p<.05), 
there were no significant adolescent/adult differences. 
 Twelve months later, 93% obtained a CUD diagnosis 
(76% dependence, 17 % abuse, 74% both diagnoses). ICD-
10 diagnoses were similar (both assessments). The most 
frequently endorsed criteria were ‘use in hazardous 
situations’ (80%), then markedly increased ‘tolerance’ (79% 
vs 53%), ‘using more/longer than intended’ (79%), 
‘persistent desire to control/cut down’ (71%). Adolescents 
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endorsed a mean of 7.66 and adults 7.22 (both ranges: 0-13) 
symptoms, reflecting a significant increase among both 
adolescents, t (127) = -7.52, p<.001, and adults, t (65) = -
2.94, p<.01. Again, adolescents were more likely to report 
cannabis-induced work/school and interpersonal problems 
(p<.001) and adults more likely to report use in hazardous 
situations (driving stoned) (p<.001). 
 Dependence severity (SDS) scores depicted a similar 
pattern, with no significant adolescent/adult differences in 
scores or items endorsed at either assessment. Both groups 
scored significantly higher at follow-up (Table 3). 
Twelve-Month Diagnostic Transitions and Association 
with Key Variables 
 As Table 2 reflects, at follow-up only minor movement 
between diagnostic categories was evident; 86% (108 
adolescents, 58 adults) had remained stable/same diagnosis, 
9% (13 adolescents, 4 adults) had deteriorated (now had a 
diagnosis/progressed from abuse to dependence), while 5% 
(7 adolescents, 4 adults) had ‘improved’ (dependence to 
abuse/now in remission). 
 The ‘deteriorated’ transition group included 4 (of 12) 
baseline diagnostic orphans: one obtaining dependence, and 
3 abuse, diagnoses; one asymptomatic adolescent now with 
abuse, and 8 adolescents and 4 adults had progressed from 
abuse to dependence, diagnoses. 
 The ‘improved’ transition group comprised 3 adults and 
6 adolescents with dependence reducing to abuse diagnoses, 
one adolescent from abuse to diagnostic orphan, and one 
adult from abuse to remission. 
 Other noteworthy baseline (no diagnosis) transitions 
included: 7 (of 12) diagnostic orphans remained unchanged, 
and one now in remission; three (of 5) baseline 
asymptomatic adolescents had become diagnostic orphans, 
with only one remaining symptom-free. 
 We compared, via a series of independent samples t-tests, 
‘deteriorated’ and ‘improved’ groups on this study’s key 
variables (Table 4). One set of analyses reports differences 
between the two groups at baseline (B). The second set of 
analyses considers differences between the two groups at 
follow- up (F-U). 
 As Table 4 indicates, there were no differences between 
the two diagnostic transition groups at baseline (B) in terms 
of cannabis use, with the exception of the adult subgroup 
where the ‘improved’ group reported significantly less 30-
day cannabis use than the ‘deteriorated’ group. Adolescent 
‘improvers” reported significantly higher symptoms and 
SDS scores at baseline than adolescent ‘deteriorators’. 
Table 1. Patterns of Cannabis Use Among the Baseline and Follow-Up Samples (n=194) 
 
Variable Adolescents (<=18 Yrs) 
(n=128) 




 Baseline Follow-Up Baseline Follow-Up Baseline Follow-Up 
Age of first use (yrs)       
Mean 12.10  14.57  12.94  
SD 1.85  4.41  3.19  
Range 4 – 16  5 – 32  4 – 32  
Ever regular use? (weekly +) (%) 113 (88.3)  66 (100)  179 (92)  
Age of first regular use (weekly +) (yrs)       
Mean 13.47  17.61  14.98  
SD 1.74  5.39  4.04  
Range 8 – 17  10 – 40  8 – 40  
Number of years regular use        
Mean 1.81  10.92  5.12  
SD 1.46  7.91  6.57  
Range 0 – 12  0 – 37  0 – 37  
Days of use past 90 days        
Mean 45.04 53.46 62.70 58.33 51.04 55.12 
SD 29.16 32.50 30.70 32.50 30.78 32.57 
Range 0 – 90 0 – 90 0 – 90 0 – 90 0 – 90 0 – 90 
Days of use past 30 days        
Mean 14.98 17.65 21.62 19.43 17.24 18.26 
SD 10.26 11.05 10.72 11.01 10.86 11.04 
Range 0 – 30 0 - 30 0 – 30 0 - 30 0 – 30 0 - 30 
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 At follow up (F-U) there were consistent differences 
between the diagnostic transition groups in terms of both 
cannabis use and total symptoms. Individuals whose 
diagnosis had deteriorated were using significantly more 
cannabis and had significantly higher symptom levels. These 
same individuals also reported higher SDS scores at follow 
up (although the difference was not significant for the 
adolescent sub-group). 
Quit Attempts and Treatment-Seeking 
 Two-thirds (69%) of the sample reported unsuccessfully 
attempting to quit/reduce their use prior to baseline and 55% 
(n=107) reported doing so within the follow-up period, most 
(n=77) without assistance. While treatment seekers (17 
adolescents, 13 adults) and non-seekers reported similar 
baseline use, at follow-up treatment seekers’ use level was 
significantly higher than non-seekers in the past 90 [t (105) = 
-2.80, p <.01] and 30 [t (105) = -2.85, p <.01] days, 
explained by the adolescents. Nevertheless, 86% (both 
assessments) believed they did not require any help to cut 
down/quit. 
DISCUSSION 
 This naturalistic, prospective study examining cannabis 
use and disorders among a mixed adolescent-adult 
community and treatment-seeking sample reporting high 
levels of cannabis use at baseline found 90% met criteria for 
a 12-month DSM/ICD diagnosis of CUD. Twelve months 
later, significantly increased cannabis consumption 
(adolescents), symptoms, and dependence severity were 
reported, with no significant adolescent/adult differences 
evident. As in local [19] and international [16-18] 
prospective research, rather than a tailing-off or remission, 
there was clear evidence of generally-persisting use among 
Table 2. Proportion (%) of Adolescents and Adults Meeting 12-Month DSM-IV/ICD- 10 Diagnoses, and Each of the Criteria, for 
Cannabis Use Disorder on the CIDI-Auto Among Baseline and Follow-Up Samples (n=194) 
 
Variable Adolescents (<=18 Yrs) 
(n=128) 




 Baseline Follow-Up Baseline Follow-Up Baseline Follow-Up 
12-month DSM-IV Diagnoses            
Cannabis Dependence  67 73 76 82 70 76 
Cannabis Abuse only  19 18 20 15 20 17 
Cannabis Dependence & Abuse  65 73 70 77 66 74 
12-month ICD-10 Diagnoses       
Dependence Syndrome 66 72 73 80 68 75 
Harmful Use only  5 3 12 8 7 5 
Dependence Syndrome & Harmful Use  56 59 70 65 61 61 
No Diagnosis  12.5 9.4 1.5 3.0 8.8 7.2 
‘Diagnostic orphans’ (1 or 2 dependence criteria) 9.4 7.8 0 1.5 6.2 5.7 
No symptoms/criteria 3.1 1.6 1.5 1.5 2.6 1.5 
Dependence Criteria Met        
Tolerance: need more to achieve desired effect (or) same amount has less effect. 53 80 50 76 51 79 
Withdrawal symptoms when cut down (or) use to avoid/relieve symptoms.   26 48 44 44 32 47 
Used more, or over longer periods, than intended. 69 77 79 83 72 79 
Strong desire to use/compulsive use. 43 52 53 58 46 54 
Persistent desire (or) unsuccessful efforts to cut down or control use. 62 66 67 79 63 71 
Great deal of time spent using, obtaining, or recovering. 61 52 71 64 64 56 
Important social, occupational or recreational activities given up or reduced because of  
cannabis use 31 55 29 30 30 47 
Continued use despite persistent cannabis-related medical problems 22 20 29 21 24 20 
(or)       
Continued use despite persistent cannabis-related psychological problems 49 61 62 64 54 62 
Abuse/Harmful Use Criteria Met       
Interfered with role obligations at work, school, or home 45 66 24 27 38 53 
Recurrent use in physically hazardous situations 74 74 82 92 77 80 
Recurrent legal problems 26 36 23 38 25 37 
Recurrent social/interpersonal problems caused or exacerbated by cannabis use 48 78 33 47 43 68 
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adults and significantly increased use among adolescents. 
More than half had tried to reduce/quit their cannabis 
consumption without success. Nevertheless, despite having 
worried and wishing they could stop (Table 3), the majority 
(86%) paradoxically believed their cannabis use was not a 
problem in their lives. Younger users in particular appeared 
to have little knowledge or insight (and frequently none 
whatsoever) into cannabis’ dependence/harm liability or its 
role in their life problems. 
 The sample’s predominantly youthful profile (two-thirds 
younger than 18 years, early-onset use, other drug use, low 
SES, low educational level, not enrolled/expelled from 
regular school, unemployed) accords with ‘excess’ risk of 
cannabis dependence globally [28, 49-52]. A growing group 
of young New Zealanders are raised in ‘cannabis 
environments’ where cannabis is ‘normalized’ and inter-
generational use is common [53]. Most adolescents (86%) 
reported familial drug problems usually involving cannabis, 
and having partners (66%) and parents (30%) who used 
cannabis regularly. More than a third reported cannabis-
related expulsions or suspensions - often multiple - from 
school. Using more potent cannabis products on at least 2 
and up to 5 or more days (89%) per week, and feeling 
‘stoned’ at least 3 hours per day (65%) exposed these New 
Zealand adolescents to risk of manifold harms, a 
vulnerability amplified by significantly increased alcohol 
and BZP use. Among society’s most vulnerable [49-52], 
these at-risk youth epitomize the primary intended recipients 
of a screening and early intervention (SEI) approach. 
 A primary empirical question in this study was: do 
adolescents and adults exhibit different cannabis 
consumption, symptoms, and dependence severity profiles? 
Table 3. Descriptive Statistics for the Severity of Dependence Scale (SDS):  Individual items and Total Score Among Adolescents 
and Adults at Baseline and Follow-Up 
 
Scale Item Adolescents (< = 18 Years) (n = 128) Adults (19+ Years) (n = 66) 
 Baseline Follow-up Baseline Follow-Up 
During the last 6 months…….   M  (SD) M  (SD) M  (SD)   M  (SD) 
Did you ever think your use of cannabis was out of control? .52  (.69) .81 (.82) *** .60 (.89) .77 (.85) 
Did the prospect of missing a smoke make you very anxious or worried?  .66 (.81) 1.08 (.81) *** .88 (.94) .89 (.70) 
How much did you worry about your cannabis use?  .88 (.66) 1. 3 (1.9) * 1.03 (.82) 1.27 (.73) * 
Did you wish you could stop? .91 (.75) 1.13 (1.2) * .95 (.88) 1.20 (.96) * 
How difficult would you find it to stop or go without cannabis?    1. 00 (.82) 1.38 (.96) *** 1.10 (.88) 1.44 (.79) ** 
Total SDS Score 4. 00 (2.4) 5.50 (3.0) *** 4.57 (3.2) 5.56 (2.8) ** 
M: mean. SD: standard deviation.  * p < .05, ** p < .01, *** p < .001; all tests two-tailed.   
Table 4. Key Variables Associated with Diagnostic Transitions at Baseline and 12-Month Follow-Up (n=28) 
 
Diagnostic Transition Group  
Improved  (n=11) Deteriorated (n=17)  
Baseline Follow Up Baseline Follow Up t 
Variable 
Mean SD Mean SD Mean SD Mean SD B F - U 
Cannabis Use (n=28) 
Days used past 90 days 23.09 25.93 14.36 14.21 34.94 25.59 50.88 25.99 1.19 4.25*** 
Days used past 30 days 7.91 8.96 5.09 5.17 12.47 9.46 17.88 8.85 1.27 4.33*** 
Adolescents (n=20) 
 Days used past 90 days 31.29 29.49 16.14 16.90 32.00 24.76 43.46 22.47 .06 2.80* 
 Days used past 30 days 11.00 10.05 5.86 6.09 10.54 7.87 15.07 7.68 -.11 2.73* 
Adults (n=8) 
Days used past 90 days 8.75 8.38 11.25 8.99 44.50 29.72 75.00 23.80 2.32 5.01** 
Days used past 30 days 2.50 2.08 3.75 3.30 18.75 12.69 27.00 6.00 2.53 * 6.78** 
Total symptoms (n=28) 4.09 1.87 2.73 1.42 2.76 1.56 6.65 2.47 -2.03 4.75 *** 
Adolescents (n=20) 3.86 1.46 2.71 1.25 2.38 1.39 6.38 2.60 -2.22 * 3.49 *** 
Adults (n=8) 4.50 2.65 .75 1.89 4.00 1.63 7.50 2.08 -.32 3.38 * 
SDS score (n=28) 2.45 1.81 2.82 1.17 2.18 1.19 4.06 1.35 -.49 2.59* 
Adolescents (n=20) 3.43 1.40 2.86 1.35 2.00 1.00 3.77 1.36 -2.66 * 1.43 
Adults (n=8) .75 .96 2.75 .96 2.75 1.71 5.0 .82 2.04 3.58 ** 
SD: Standard deviation.   B: baseline.   F-U: follow-up.   t: t-test value.   * p < .05, ** p < .01, *** p < .001;   all tests  two-tailed. 
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Consistent with global trends, adolescents had initiated and 
begun regular use earlier than their adult counterparts (Table 
1). No adolescent/adult differences in number of symptoms 
(Table 2) or dependence severity (Table 3) were reported. 
Apart from adolescents more likely to report cannabis-
impaired functioning at school/work or home (both 
assessments), and adults more likely to report withdrawal 
(baseline) and use in hazardous situations (follow-up), there 
were no significant adult/adolescent differences in likelihood 
of endorsing any DSM-IV/ICD-10 criteria. Juxtaposed with 
their physical and psychological developmental 
vulnerability, these indices indicate that despite substantially 
shorter using histories, adolescents in this sample were 
equally as disordered as their older, longer-using 
counterparts. 
 A second primary aim was to distinguish common 
transition groups according to participants’ diagnoses at 
follow-up. Twelve-month data revealed only minor 
movement between diagnostic categories (Table 2). 
Reporting reduced symptoms does not necessarily indicate a 
less serious diagnosis. The sample’s overall longitudinal 
diagnostic stability (166 unchanged) limited comparisons to 
two small transition groups (Table 4). The results that 
emerged were not unexpected: with few minor exceptions, 
while the 2 groups reported generally similar baseline levels 
of cannabis use, symptoms and severity, at follow-up the 17 
adolescents/adults who had ‘deteriorated’ recorded 
significantly higher levels of cannabis use, symptoms, and 
dependence severity than the 11 adolescents/adults who had 
‘improved’. 
 The prevalence, constellation, and progression of CUD 
symptoms were another study question. As found in US 
research among users on a trajectory towards dependence 
[27-29], ‘use in physically hazardous situations’ was most 
prevalent overall, and loss of control over use (‘persistent 
desire to control/cut down’/‘used more/longer than 
intended’) the most prevalent dependence criterion. 
Moreover, this criterion was the only (hence earliest) 
dependence feature endorsed by all 12 baseline diagnostic 
orphans. At 12-month follow-up, the 11 diagnostic orphans 
(who now included 3 baseline symptom-free participants) all 
reported ‘loss of control over use’ .symptoms. 
 Given the controversy about cannabis’ physical 
dependence liability [54, 55], the striking 12-month increase 
in adolescents’ tolerance (80% up from 54% at baseline) and 
withdrawal symptoms (48% up from 28%) merits comment. 
Tolerance and withdrawal have been frequently reported by 
dependent and non-dependent adolescents alike [31, 32]. 
Adolescents with marked tolerance to cannabis underwent 
clinically severe withdrawal symptoms over several weeks, 
their intensity unrelated to quantity or frequency of 
consumption, length of dependence, or age when regular use 
began [56]. Hartman et al. [57] concluded that adolescents 
endorsing ‘withdrawal’ criteria were likely to have the most 
severe cannabis problems. Indeed, both anecdotally and in 
response to measures in this study, many younger 
participants expressed despair at their own inability to quit or 
reduce their consumption. Whatever the susceptibility 
mechanism, younger adolescent users do appear especially 
vulnerable to neuroadaptation to cannabis and developing  
 
symptoms of physiological dependence [57, 58]. Hence, 
harnessing a burgeoning variety of innovative technology-
delivered interventions [59], public health SEI initiatives 
should target vulnerable adolescents at risk/on a trajectory to 
cannabis dependence to arrest transition to more serious 
harms. Specifically developed and/or validated for 
adolescent and adult general and clinical populations, 
appropriate screening tools include the Cannabis Use 
Problems Identification Test [37] and the SDS [45]. 
 Potential limitations of this naturalistic study of a 
relatively small convenience community sample of at-risk 
adolescent-adult users must be acknowledged. The self-
report, repeated-measures design raises possible reliability 
issues. All indicators, however, including toxicology reports 
and informal internal comparisons of participants’ responses 
suggest over/under-reporting to be minimal, as found 
elsewhere [60, 61]. The prospective data overcomes biases in 
most previous retrospective studies, and adolescents’ 
restricted age range constrains a potential length (of use) bias 
and period (social trends, potency) effects. The face-to-face, 
standardized assessments (participants being their own 
longitudinal control) contrast to the relatively crude 
epidemiological surveys typically conducted. Given the 
interviewer’s strict adherence to the CIDI-Auto guidelines, 
with cautious use of diagnostic concepts and terminology, 
and with no negative consequences for admitting 
cannabis/other drug use, adolescents’ ready identification 
with dependence symptoms provide some assurance of the 
integrity of the process and the data generated. The sample’s 
overall longitudinal diagnostic stability, and hence relatively 
small diagnostic transition groups to compare, limited the 
potential scope of analyses on available data. Finally, this 
study of a relatively small community convenience sample 
of at-risk cannabis users spanned a 24-month (12 months 
retrospective) window. More longitudinal studies that 
employ systematic sampling procedures to recruit a broader 
range of cannabis-using populations from both clinical and 
non-clinical community settings are required. Larger, more 
representative, more clinically-diverse and ethnically 
proportionate samples stratified by age, cannabis 
consumption levels, and spanning more elapsed time, are 
needed to obtain a clearer ‘before’ picture of adolescent 
cannabis users’ transition from non-problematic, to regular, 
to symptom manifestation, to dependence. Fuller 
understanding of various pathways provides the foundation 
needed for effective targeted interventions. 
CONCLUSION 
 While extending the international research on the natural 
history of CUD, this prospective New Zealand study 
confirms that younger adolescents can - and do - rapidly 
develop cannabis dependence, reporting similar and equally 
severe symptoms as longer-term adult users. The ostensibly 
inexorable course of problematic cannabis use makes a 
compelling case for stronger investment in public health SEI 
initiatives at an early age to avert or reduce harmful 
consequences of cannabis use in the community. 
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